Literature DB >> 11581235

Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones.

J Ruiz1, A Jurado, E Garcia-Méndez, F Marco, L Aguilar, M T Jiménez de Anta, J Vila.   

Abstract

We studied the frequency of mutation of clinical isolates of Neisseria gonorrhoeae (two nalidixic acid susceptible and two nalidixic acid resistant), and the stability of the mutants obtained, in the presence of three different concentrations of five fluoroquinolones. The frequency of mutation was low for all the quinolones. Only one N. gonorrhoeae mutant, obtained with trovafloxacin at 4 x MIC presented a stable increase in the MIC of this quinolone, not attributable to novel mutation(s), both in the gyrA and parC genes, although not showing any increase in the MIC of the other quinolones tested. In summary, gemifloxacin was the only quinolone tested for which resistant mutants were not obtained.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11581235     DOI: 10.1093/jac/48.4.545

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae.

Authors:  D J Farrell; H S Sader; P R Rhomberg; N E Scangarella-Oman; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

2.  Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Authors:  Gregory S Basarab; Gunther H Kern; John McNulty; John P Mueller; Kenneth Lawrence; Karthick Vishwanathan; Richard A Alm; Kevin Barvian; Peter Doig; Vincent Galullo; Humphrey Gardner; Madhusudhan Gowravaram; Michael Huband; Amy Kimzey; Marshall Morningstar; Amy Kutschke; Sushmita D Lahiri; Manos Perros; Renu Singh; Virna J A Schuck; Ruben Tommasi; Grant Walkup; Joseph V Newman
Journal:  Sci Rep       Date:  2015-07-14       Impact factor: 4.379

3.  Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations.

Authors:  Anjali N Kunz; Afrin A Begum; Hong Wu; Jonathan A D'Ambrozio; James M Robinson; William M Shafer; Margaret C Bash; Ann E Jerse
Journal:  J Infect Dis       Date:  2012-04-05       Impact factor: 5.226

4.  In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance.

Authors:  Olusegun O Soge; Stephen J Salipante; David No; Erin Duffy; Marilyn C Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

5.  Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.

Authors:  Richard A Alm; Sushmita D Lahiri; Amy Kutschke; Linda G Otterson; Robert E McLaughlin; James D Whiteaker; Lisa A Lewis; Xiaohong Su; Michael D Huband; Humphrey Gardner; John P Mueller
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

6.  A national survey of the knowledge, attitudes and prescribing practices of doctors regarding antibiotic resistance in a Caribbean country.

Authors:  Alison Nicholson; Ingrid Tennant; Livingston White; Camille-Ann Thoms-Rodriguez; Loraine Cook; Stephen Johnson; Tamara Thompson; Jasper Barnett; Lundie Richards
Journal:  Antimicrob Resist Infect Control       Date:  2018-02-15       Impact factor: 4.887

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.